

# Denver Business Journal Names Strive Health CEO Among Colorado's Most Admired CEOs

10/5/2023

The award recognizes Chris Riopelle's outstanding leadership and commitment to Strive's success, workplace wellness and philanthropy

DENVER--(BUSINESS WIRE)-- Denver Business Journal announced that Chris Riopelle, CEO and co-founder of **Strive Health**, was named a Most Admired CEO. **Denver Business Journal's Most Admired CEO Awards** program recognizes distinguished top executives, and winners are selected based on their leadership, contributions to company success, civic engagement and career achievements.

Strive Health's Chief Executive Officer, Chris Riopelle, has been recognized as a 2023 Most Admired CEO Award winner by the Denver Business Journal. (Photo: Business Wire)

Riopelle is part of the team that has led Strive to serve 100,000 patients across 30 states,

partner with over 700 nephrology providers and grow its employee base to over 600 Strivers. The company's value-based care approach to kidney disease has led to over 20% reduction in the total cost of kidney care,<sup>1</sup> 42% reduction in hospitalizations<sup>2</sup> and 88% overall patient satisfaction with Strive's staff.<sup>3</sup> Riopelle has also been a pillar in the kidney care industry and Denver healthcare community for more than 25 years. He serves as a board member and past President of the Board of Trustees of the Crested Butte Land Trust.

"It's an honor to be recognized by Denver Business Journal among other incredible local leaders and continue to raise awareness of kidney disease and provide hope to patients by changing the way the healthcare industry thinks about a disease that currently impacts 37 million Americans," Riopelle said. "This award is a testament to our team of Strivers and the progress we've made over the past five years in evolving how we care for people with kidney disease by identifying patients earlier, prioritizing the right care at the right time, driving better outcomes and

lowering total cost of care.”

This recognition comes at a time of significant momentum for Strive. In the past year, Strive announced its **Series C funding**, raising \$166 million led by NEA alongside five new investors, including large strategic investor CVS Health Ventures. The company also became the fastest-growing startup in Colorado, **according to The Leaderboard and Crunchbase**. Additionally, because of Riopelle’s commitment to transparency and openness in the workplace, the company has won five Best Places to Work awards, including Forbes America’s Best Startup Employers 2022 and 2023, Built In Colorado Best Places to Work 2022, Comparably’s Best Places to Work in Denver 2022 and The Tech Tribune’s Best Startups in Denver 2022.

To learn more about Strive and its award-winning leadership team and company culture, visit <https://strivehealth.com/>.

## ABOUT STRIVE HEALTH

Strive Health is the nation’s leader in value-based kidney care and partner of choice for innovative healthcare payors and providers. Using a unique combination of technology-enabled care interventions and seamless integration with local providers, Strive forms an integrated care delivery system that supports the entire patient journey from chronic kidney disease (CKD) to end-stage kidney disease (ESKD). To help patients, Strive partners with commercial and Medicare Advantage payors, Medicare, health systems and physicians through flexible value-based payment arrangements, including risk-based programs. Strive serves 100,000 people with CKD and ESKD across 30 states and partners with over 700 nephrology providers. Strive’s case management and population health programs are accredited by the National Committee for Quality Assurance (NCQA), and its technology platform, CareMultiplier™, is certified by HITRUST. To learn more, visit [StriveHealth.com](https://StriveHealth.com).

1. Calculated through comparing PMPM trends between Medicare fee-for-service data from a Strive Health partnership analyzing patient data from a mature market.
2. Calculated by comparing 2021 USRDS blended average of hospitalization prevalence from CKD3 through ESRD patients to that of Strive Health patient data.
3. Based on a market-specific Strive Health patient satisfaction survey of all patients actively seeing a clinician in Fall 2022.

Nicole Leatherman

Strive Health Communications

619-917-4807

[nleatherman@strivehealth.com](mailto:nleatherman@strivehealth.com)

Source: Strive Health